| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Altenuene does not have a well-defined molecular target. It exhibits antioxidant activity and inhibits cholinesterases. It has also demonstrated moderate activity against Staphylococcus aureus. As a mycotoxin, it may exert toxic effects through multiple mechanisms, including oxidative stress induction, enzyme inhibition, and disruption of cellular signaling pathways. The compound's primary pharmacological interest lies in its potential as a lead compound for antimicrobial or antioxidant drug development.
|
|---|---|
| ln Vitro |
In vitro, altenuene demonstrates moderate antibacterial activity against Staphylococcus aureus. It also exhibits antioxidant activity and inhibits cholinesterases. Altenuene has been evaluated in various cell lines including lung cancer A549, breast cancer MDA-MB-231, and pancreatic cancer PANC-1, although specific IC50 values are not readily available. The compound's bioactivity is attributed to its phenolic and chromenone structural features, which are characteristic of many bioactive natural products.
|
| ln Vivo |
In vivo activity of altenuene has not been extensively reported. As a mycotoxin, its primary relevance is in food safety and toxicology, rather than therapeutic applications. Contamination of food and feed with Alternaria toxins, including altenuene, is a concern for human and animal health. No significant in vivo pharmacological activity has been reported in the literature, and the compound is not used as a therapeutic agent.
|
| Enzyme Assay |
In vitro enzyme assays for altenuene typically involve measuring its antioxidant activity and cholinesterase inhibition. For antioxidant activity, the DPPH (2,2-diphenyl-1-picrylhydrazyl) radical scavenging assay is commonly used, where the compound is incubated with DPPH and the decrease in absorbance is measured. For cholinesterase inhibition, the Ellman's assay is employed, where the compound is incubated with acetylcholinesterase or butyrylcholinesterase and the substrate acetylthiocholine, and the production of thiocholine is monitored colorimetrically.
|
| Cell Assay |
In vitro cell-based assays for altenuene involve culturing cancer cell lines such as A549 (lung), MDA-MB-231 (breast), or PANC-1 (pancreatic) and treating them with various concentrations of the compound. Cells are seeded in multi-well plates, allowed to adhere, and then treated with altenuene for 24-72 hours. Cell viability is assessed using MTT, CellTiter-Glo, or SRB assays. IC50 values for cytotoxicity are calculated from dose-response curves. Antibacterial activity is assessed using broth microdilution assays to determine minimum inhibitory concentrations (MICs).
|
| Animal Protocol |
In vivo animal studies for altenuene are primarily conducted in the context of toxicology and food safety rather than therapeutic efficacy. Rodent models may be used to assess the acute and chronic toxicity of Alternaria toxins, including altenuene. Animals are administered the compound orally or intraperitoneally at various doses, and clinical signs, body weight, food consumption, clinical pathology, and histopathology are evaluated. No specific therapeutic efficacy studies have been reported.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of altenuene have not been extensively characterized. As a small molecule (molecular weight 292.28) with multiple hydroxyl groups, it is expected to have moderate aqueous solubility and may undergo rapid metabolism and excretion. Mycotoxins are typically metabolized in the liver by cytochrome P450 enzymes and excreted in urine and feces. The compound's bioavailability would depend on its stability in the gastrointestinal tract and first-pass metabolism. No specific PK data are available.
|
| Toxicity/Toxicokinetics |
The toxicity profile of altenuene is primarily associated with its role as a mycotoxin. Alternaria toxins, including altenuene, are contaminants of food and feed and pose health risks to humans and animals. Toxicological studies have focused on the compound's potential to cause genotoxicity, cytotoxicity, and immunotoxicity. The compound exhibits moderate activity against Staphylococcus aureus, indicating some antimicrobial potential, but also suggesting potential for cytotoxicity. Standard toxicology assessments would include acute, sub-chronic, and chronic toxicity studies in rodents.
|
| References | |
| Additional Infomation |
Altenuene has been reported to be found in Urspora rice, Altenuene alternata, and other organisms with available data.
Altenuene is a mycotoxin and research compound, not approved for clinical use. It is a heptaketide isolated from Alternaria fungi and endolichenic strains such as Nigrospora sphaerica. The compound has the molecular formula C15H16O6 and a molecular weight of 292.28. It exhibits antioxidant activity, cholinesterase inhibition, and moderate antibacterial activity against Staphylococcus aureus. Altenuene is primarily of interest in the context of food safety, toxicology, and natural product chemistry. |
| Molecular Formula |
C15H16O6
|
|---|---|
| Molecular Weight |
292.28
|
| Exact Mass |
292.095
|
| CAS # |
29752-43-0
|
| Related CAS # |
(-)-Altenuene;889101-41-1
|
| PubChem CID |
34687
|
| Appearance |
White to off-white solid powder
|
| Vapour Pressure |
1.05E-15mmHg at 25°C
|
| Source |
Originated from microorganisms: Alternaria alternata
|
| LogP |
0.838
|
| tPSA |
96.22
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
21
|
| Complexity |
475
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
C[C@]12C[C@@H]([C@H](C=C1C3=C(C(=CC(=C3)OC)O)C(=O)O2)O)O
|
| InChi Key |
MMHTXEATDNFMMY-WBIUFABUSA-N
|
| InChi Code |
InChI=1S/C15H16O6/c1-15-6-12(18)10(16)5-9(15)8-3-7(20-2)4-11(17)13(8)14(19)21-15/h3-5,10,12,16-18H,6H2,1-2H3/t10-,12-,15-/m0/s1
|
| Chemical Name |
(2S,3S,4aS)-2,3,7-trihydroxy-9-methoxy-4a-methyl-3,4-dihydro-2H-benzo[c]chromen-6-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~342.1 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4214 mL | 17.1069 mL | 34.2138 mL | |
| 5 mM | 0.6843 mL | 3.4214 mL | 6.8428 mL | |
| 10 mM | 0.3421 mL | 1.7107 mL | 3.4214 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.